FeesSafety
Pluang+

NewLake Capital Partners remains a Strong Buy with 12.4% dividend yield and debt-free balance sheet.

Analyst Insights
11 Nov 2026, 22:06 WIB
Seeking Alpha
View Source
Bullish
NewLake Capital Partners remains a Strong Buy with 12.4% dividend yield and debt-free balance sheet.

NewLake Capital Partners is rated Strong Buy due to its attractive 12.4% dividend yield and a debt-free balance sheet. Despite some pressure on adjusted funds from operations (AFFO) caused by vacancies, the company maintains strong operational resilience with 99.7% rent collection year-to-date and active re-tenanting efforts. Key growth catalysts include potential cannabis rescheduling progress, an exchange uplisting, and opportunities for leverage or buybacks. Its valuation appears compelling, with intrinsic value estimated well above current market levels even under conservative assumptions.

NewLake Capital Partners offers a notable 12.4% dividend yield alongside multiple growth catalysts. For readers following the Real Estate sector, here is Pluang's market snapshot as of Nov 12, 2026 00:01 WIB: out of 47 priced US Real Estate stocks, 5 rose and 42 fell. Notable movers include VMRK at USD 64.56 with a -1.81% change, OHI at USD 47.83 with a -1.79% change and 100% buy order activity, and OUT at USD 33.43 with a +1.70% change. Typical hold times range from 10 to 18 days on Pluang.

More News

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...

Market News
Bullish
1 hour ago
Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...

Bullish
2 hours ago
Across Protocol warns users to avoid app amid possible security breach causing crypto losses

Across Protocol warns users to avoid app amid possible security breach causing crypto losses

Across Protocol has advised users to avoid its app and refrain from connecting wallets or signing transactions due to a potential security incident involving its domain. Users have reported significant losses, including $9,000 in USDC and over 7,000 ...

Market News
Bearish
5 hours ago
XRP addresses holding 10,000+ tokens rose 5.15% despite a 30% price drop in 7 weeks

XRP addresses holding 10,000+ tokens rose 5.15% despite a 30% price drop in 7 weeks

The number of XRP addresses holding at least 10,000 tokens increased by 16,815 over nine months, reaching about 343,500 addresses, a 5.15% rise, even as XRP's price fell approximately 30% in seven weeks. Addresses holding one million or more XRP hit ...

Technical Signals
Neutral
5 hours ago
Nvidia remains a strong Buy with 130% upside despite CEO probe and recent share drop.

Nvidia remains a strong Buy with 130% upside despite CEO probe and recent share drop.

Nvidia Corporation continues to be a compelling Buy despite recent share price declines and an ongoing investigation involving its CEO. The demand for Nvidia's chips remains strong, fueled by capital expenditure growth from hyperscalers and robust cl...

Analyst Insights
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App